APGE · Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. Is A Biotechnology Firm, Operating Via Its Subsidiary, Dedicated To Advancing Biologic Treatments For Conditions Such As Atopic Dermatitis (Ad), Chronic Obstructive Pulmonary Disease (Copd), And A Range Of Other Inflammatory And Immunological Disorders. Its Primary Focus Includes Apg777, A Subcutaneous (Sq) Monoclonal Antibody (Mab) Engineered For An Extended Half-Life To Treat Ad, And Apg808, A Similarly Formulated Sq Extended Half-Life Mab Targeting Copd. Furthermore, Its Earlier-Stage Pipeline Features Apg990, Another Sq Extended Half-Life Mab Designed For Ad, And Apg222, Comprising Extended Half-Life Subcutaneous Antibodies Also Aimed At Ad. Established In 2022, The Company Maintains Its Headquarters In Waltham, Massachusetts.